Tafazzin Fusion Proteins for Cellular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Barth syndrome, caused by tafazzin deficiency, primarily focus on symptom management rather than addressing the underlying metabolic disorder, and there is a lack of effective therapies to restore mitochondrial function and prevent disease progression.
Innovation Solution
Development of fusion proteins comprising a tafazzin peptide coupled with a cellular permeability peptide through a polypeptide linker, which can be administered to treat or prevent disorders associated with tafazzin deficiency by facilitating the uptake of tafazzin into cells and restoring cardiolipin modification and mitochondrial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tafazzin protein is administered to treat Barth syndrome, then mitochondrial function is restored, but the protein cannot effectively enter cells due to poor cellular permeability
Solution Approach 1:
The patent applies the intermediary principle by fusing tafazzin protein with cell-penetrating peptides (CPPs) such as penetratin, TAT, or transactivator of transcription (Tat) peptides. These CPPs act as mediators that facilitate the cellular uptake of tafazzin protein, which otherwise cannot effectively enter cells. The fusion construct enables the therapeutic protein to cross the cell membrane barrier while maintaining its enzymatic function for cardiolipin remodeling.
Solution Approach 2:
The patent employs composite materials by creating fusion proteins that combine tafazzin with cell-penetrating peptides. This composite structure integrates the therapeutic function of tafazzin (cardiolipin remodeling) with the delivery function of CPPs (cellular penetration), resulting in a single molecule that possesses both therapeutic effectiveness and improved cellular uptake efficiency.
2Reliability
If current treatments focus on symptom management, then disease progression is not addressed, but developing new therapies takes time and resources
Solution Approach 1:
The patent applies preliminary action by developing and characterizing fusion protein constructs in advance, creating a ready-to-use therapeutic platform that can be quickly deployed for treating Barth syndrome. The preliminary work includes identifying effective CPPs, optimizing fusion construct designs, and validating therapeutic efficacy in preclinical models, which accelerates the transition from symptom management to disease-modifying therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion proteins effectively restore mitochondrial respiration and cardiolipin levels, improving contractile function in skeletal and cardiac muscles, and potentially delaying or preventing the onset of Barth syndrome symptoms.
Implementation Method 1
fusion proteins comprising a tafazzin peptide and a cellular permeability peptide
Implementation Method 2
Tafazzin (TAZ) is a mitochondrial transacylase that can catalyze the transfer of acyl chains from phosphatidyl choline to cardiolipin (CL), remodeling monolysocardiolipin (MLCL) to tetralinoleoyl cardiolipin (L4CL)
Implementation Method 3
Studies have shown that CL, a structurally unique phospholipid component of the inner mitochondrial membrane, can provide functional support for electron transport chain complexes
Data Source
AI summary
Fusion proteins comprising a tafazzin peptide and a cellular permeability peptide are disclosed. The tafazzin peptide may be coupled to the permeability peptide through a polypeptide linker. Methods of making and using the fusion proteins are also disclosed. For example, the disclosed fusion proteins may be used to treat a patient having a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency (e.g., Barth syndrome). Additionally, the disclosed fusion proteins may be used in prophylaxis against developing a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency in a patient at risk of developing such a disorder.